Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630885 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT05630885 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 110 participants.
The verdict
NCT05630885, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta and carotid arteries.
Interventions
- DRUG CVC 150 mg
- DRUG CVC 300 mg
- OTHER Placebo for CVC 150 mg
- OTHER Placebo for CVC 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630885
The ClinicalTrials.gov registry entry for NCT05630885 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CVC 150 mg is the first listed.
NCT05630885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05630885 about?
NCT05630885 is a clinical study titled "A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV". The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta and carotid arteries.
What is the current status of trial NCT05630885?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2023-05-30. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT05630885?
The interventions under investigation include: CVC 150 mg (DRUG), CVC 300 mg (DRUG), Placebo for CVC 150 mg (OTHER), Placebo for CVC 300 mg (OTHER).
Who is sponsoring clinical trial NCT05630885?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.